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CC BY-NC-ND license (http://creativeBackground: Although the mortality rates have decreased over the past few decades, neonatal
meningitis is still a severe disease with high morbidity. Moreover, approximately 40% of survi-
vors exhibit neurological sequelae. Escherichia coli is the major Gram-negative bacterial path-
ogen in neonatal meningitis. The N-terminal b-barrel domain of the outer membrane protein A
(OmpA) of E. coli is essential for effective protein conformation and function and contains four
surface-exposed hydrophilic loops. In this study, we expressed different fragments of the four
ring structures of the N-terminal domain, and investigated whether these recombinant OmpA
fragments can protect mice from death after E. coli infection.
Methods: We expressed the recombinant proteins of the following OmpA fragments by using
molecular cloning of Loop 1e2, Loop 1e3, Loop 1e4, Loop 2e3, Loop 2e4, and Loop 3e4. An-
imal experiments were subsequently performed to investigate the effects of these recombi-
nant OmpA fragments on the survival of C57BL/6 mice after intracerebral E. coli RS218
administration.
Results: This study demonstrated that the recombinant Loop 1e3, Loop 2e3, and Loop 2e4
fragments of OmpA can protect mice from intracerebral E. coli infection.dical Laboratory Science and Biotechnology, Taipei Medical University, Number 250, Wu-Hsing Street,
(H.-H. Wu).
.07.012
Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
330 W.-S. Hsieh et al.Conclusion: In bacterial meningitis, although antibiotic therapy is the first choice for manage-
ment, neurological complications can seldom be averted. Based on the results of the present
study, we intend to establish an effective therapeutic application for E. coli meningitis.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Figure 1. N-terminal, surface-exposed, OmpA fragments:
Loop 1e2, Loop 1e3, Loop 1e4, Loop 2e3, Loop 2e4, and Loop
3e4.Introduction
Despite the availability of advanced antibiotic therapy
and patient care for bacterial meningitis, it is still asso-
ciated with a relatively high morbidity and mortality.
Nearly 40% of surviving patients experience various
neurological complications.1e3 The pathological compli-
cations of bacterial meningitis include cerebritis, brain
abscess, empyema, and ventriculitis in the acute phase
and the sequelae of cerebral atrophy, hydrocephalus,
seizure, and hearing impairment. Seizures are the most
common complication, followed by hydrocephalus and
hearing impairment.3,4 A neuronal injury associated with
bacterial infection of the central nervous system involves
multiple microbial and host factors; Escherichia coli
strains with the K1 capsular polysaccharide are the most
predominant Gram-negative bacteria associated with
neonatal bacterial meningitis.5 Severe bacteremia and
invasion through brain microvascular endothelial cells
(BMECs) are the determining factors contributing to
central nervous system infection.6 Several K1-associated
components participate in BMEC binding and invasion,
including Fim H, K1 capsule, and outer membrane protein
A (OmpA).7e11 OmpA is a major outer membrane protein
of E. coli and is essential in maintaining the integrity of
the outer membrane and in bacterial conjugation.12e14
This protein is also the receptor for several
bacteriophages.15e18 OmpA is encoded using a 1,038-bp
open reading frame consisting of a 21-amino acid leader
peptide and a mature 325-amino-acid protein. Moreover,
the N-terminal membrane-anchoring domain of OmpA
forms an antiparallel b-barrel, which has eight trans-
membrane b-strands connected by three short periplas-
mic turns and four relatively large surface-exposed
hydrophilic loops; the OmpA C-terminal domain interacts
with the peptidoglycan layer in the periplasm to maintain
outer membrane integrity.19 Furthermore, OmpA is highly
conserved through the evolution of Gram-negative bac-
teria and is crucial for E. coli binding and the invasion of
BMECs and astrocytes.20,21 We previously reported that
the recombinant full-length OmpA protein can protect
mice from death after E. coli infection.21 This has
therefore encouraged study into a new therapeutic
approach to improve the prognosis of bacterial meningi-
tis. In this study, we expressed different fragments of the
four ring structures of the N-terminal domain that were
exposed on the surface of the OmpA protein, including
Loop (L) 1e2, L1e3, L1e4, L2e3, L2e4, and L3e4 (Fig. 1),
and investigated whether these recombinant OmpA
fragments can protect mice from death after E. coli
infection.Materials and methods
Chemicals, bacteria, and culture media
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA), unless otherwise indicated. The E. coli strains
used in the present study were kindly provided by Dr K.S.
Kim (Division of Pediatric Infectious Diseases, School of
Medicine, Johns Hopkins University, Baltimore, MD, USA);
RS218 (O18:K1:H7) was isolated from the cerebrospinal
fluid of a neonate with meningitis.20 E91 is an RS218 mutant
that lacks the entire ompA gene. The bacteria were grown
in braineheart infusion broth with appropriate antibiotics
(Difco Laboratories, Detroit, MI, USA). For infection ex-
periments, overnight cultures were expanded in
braineheart infusion broth and incubated at 37C for 2e3
hours to the midlog phase. The bacteria were centrifuged
at 10,000  g for 5 minutes and resuspended in a cell cul-
ture medium without antibiotics.
Mouse strain
C57BL/6 mice were obtained from the National Laboratory
Animal Center of Taiwan, Nangang, Taipei, Taiwan and
maintained under pathogen-free conditions. All animal
procedures were performed according to the approved
institutional protocol (LAC-99-0009) of Taipei Medical Uni-
versity, Taipei, Taiwan.
Expression and purification of OmpA fragments
The DNA fragments of the ompA L1e2, L1e3, L1e4, L2e3,
L2e4, and L3e4 were amplified using polymerase chain
reaction with restriction enzyme sites containing primers.
These fragments were subsequently digested with SacI and
XhoI and ligated into the pET-21a expression vector
(Novagen, Darmstadt, Germany). The resultant plasmid was
OmpA protection from E. coli meningitis 331transformed into E. coli BL21 (DE3). Protein expression was
induced by administering 0.5 mmol/L of isopropyl-b-D-thi-
ogalactopyranoside. His-recombinant proteins were then
purified using Ni2þ-charged sepharose according to the
manufacturer’s instructions (Amersham plc, Amersham,
UK). The His-recombinant proteins were eluted using an
elution buffer (20 mmol/L of sodium phosphate, 500 mmol/
L of NaCl, and 500 mmol/L of imidazole). The samples were
massively dialyzed against the elution buffer without
imidazole and then into phosphate-buffered saline (PBS; pH
7.4) to reduce the salt concentrations.
Animal experiments
In this experiment, 8e12-week-old C57BL/6 mice were
randomly distributed into groups. The experimental pro-
tocol developed by Tsao et al22 was followed to assess the
survival of mice after intracerebral bacterial administra-
tion. Each group containing five mice was anesthetized with
pentobarbital sodium salt (50 mg/kg) by intraperitoneal
injection; each brain was then infected with E. coli RS218
(5  105 in 20 mL of PBS). Concurrently, PBS (20 mL) was
used as a negative control. The mice were monitored for
survival every 12 hours for 8 days. To investigate the effects
of the recombinant OmpA fragments on the survival of the
C57BL/6 mice after intracerebral E. coli RS218 adminis-
tration, each brain was infected with E. coli RS218 (5  105
in 20 mL of PBS) by intracerebral injection in the presence
of each recombinant OmpA fragment (20 mg); the survival
of these mice was observed for up to 8 days after admin-
istration. To detect remnant bacteria in the brain, groups
of three C57BL/6 mice were infected with E. coli RS218 by
intracerebral injection in the presence or absence of each
recombinant OmpA fragment. The mice were euthanized at
various time points after the challenge. The brains were
aseptically removed and homogenized with 3% gelatin in
PBS. These samples were serially diluted, and the colony-
forming unit for each sample was determined on a blood
agar plate.
Statistical analysis
The results were expressed as the mean  standard devi-
ation of independent experiments. Quantitative andFigure 2. Purified recombinant OmpA fragments (A) displayed
immunoblotted using chicken anti-OmpA IgY (1:5000) and HRP-con
reactive bands were visualized with DAB. OmpA Z outer membranqualitative variables were analyzed using the Krus-
kaleWallis one-way analysis of variance or Student t tests,
when appropriate. The results were considered significant
when the calculated p < 0.05.Results
Expression and purification of recombinant ompA
fragments
The DNA fragments of ompA L1e2, L1e3, L1e4, L2e3,
L2e4, and L3e4 were amplified with polymerase chain re-
action and then incorporated into the pET-21a expression
vector and subsequently transformed into the E. coli BL21
(DE3) strain. The His-recombinant proteins were expressed
and purified. Moreover, homogeneities of the purified
HiseOmpA fragments were identified using the Coomassie
blue staining method and confirmed using immunoblotting
(Fig. 2A and B). The purified HiseOmpA fragment L1e2,
L1e3, L1e4, L2e3, L2e4, and L3e4 exhibited the molecu-
lar weights of 11 kDa, 15 kDa, 19 kDa, 11 kDa, 15 kDa, and
11 kDa, respectively, on 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, as predicted.Recombinant HiseOmpA fragments L1e3, L2e3,
and L2e4 protect C57BL/6 mice against E. coli
meningitis
We challenged the mice by intracerebral injection to avoid
interference of the bloodebrain barrier, according to the
protocol presented by Tsao et al.22 An infectious inoculum
of 5  105 colony-forming units/mL was used in this study.
Groups containing five C57BL/6 mice were anesthetized
and then infected with intracerebral injection of E. coli
RS218 or E91 and assessed for 8 d. As shown in Fig. 3, the
mice died within 36 h of intracerebral injection of the
OmpAþ E. coli strain RS218, with an average survival time
of 22 h (Fig. 3); by contrast, the mice challenged with the
OmpA E. coli strain E91 survived for 8 days before they
were euthanized (data not shown). This suggests that
OmpA-mediated E. coli infection subsequently results in
the death of the mice.using 10% SDS-PAGE and stained with Coomassie blue; (B)
jugated donkey anti-chicken IgY antibody (1:10000). Immuno-
e protein A.
Figure 3. Survival of C57BL/6 mice after infection with Escherichia coli RS218. Groups of 5 C57BL/6 mice were anesthetized and
challenged with 5  105 bacteria alone or a premixture of 20 mg of each His-OmpA fragment Loop 1e2, Loop 1e3, Loop 1e4, Loop
2e3, Loop 2e4, and Loop 3e4 by intracerebral injection. The mice were monitored for survival for up to 8 days. Results were
analyzed using the KruskaleWallis one-way analysis of variance.AZ indicates the average survival time of the mice (43.5 hours,
85.7 hours, 38.0 hours, 99.0 hours, 96.0 hours, and 37.0 hours for Loop 1e2, Loop 1e3, Loop 1e4, Loop 2e3, Loop 2e4, and Loop
3e4 respectively). *p < 0.05.
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HiseOmpA fragments protected the mice from the E. coli
RS218 infection. Groups of five C57BL/6 mice were chal-
lenged by intracerebral injection with a mixture of E. coli
RS218 and 20 mg of each HiseOmpA fragment (L1e2, L1e3,
L1e4, L2e3, L2e4, and L3e4), and the survival of these
mice was assessed for 8 days. The average survival times of
the mice challenged with E. coli RS218 premixed with 20 mg
of each of the HiseOmpA fragments L1e2, L1e3, L1e4,
L2e3, L2e4, and L3e4 were 43.5 hours, 85.7 hours, 38.0
hours, 99.0 hours, 96.0 hours, and 37.0 hours, respectively
(Fig. 3). These findings suggest that the recombinant
HiseOmpA fragments L1e3, L2e3, and L2e4 significantly
prolonged the survival of the C57BL/6 mice after intrace-
rebral E. coli RS218 infection (p < 0.05).
Recombinant HiseOmpA fragments L1e3, L2e3,
and L2e4 protect the C57BL/6 mice against
infection, correlating with bacterial clearance
We examined the remnant bacteria in the brain after E. coli
RS218 infection, which increased up to (2.4  0.2)  107 at
24 hours after infection and up to (6.0  0.3)  107 at 36
hours after infection (Table 1); the mice died within 36
hours of intracerebral E. coli RS218 infection. In addition,
for mice infected with E. coli RS218 premixed with re-
combinant OmpA fragments L1e2, L1e4, and L3e4, the
remnant bacteria in the brains increased up to(4.0  0.2)  106, (4.5  0.4)  106, and (5.0  0.3)  106 at
24 hours after infection, respectively, and up to
(8.6  0.1)  107, (9.2  0.0)  107, and (8.8  0.1)  107 at
60 hours after infection, respectively (Table 1); all mice
died within 72 hours after bacterial infection. By contrast,
the remnant bacteria in the brains infected with E. coli
RS218 premixed with recombinant OmpA fragments L1e3,
L2e3, and L2e4 were (5.4  0.4)  105, (3.2  0.1)  105,
and (5.5  0.4)  105 at 24 hours after infection, respec-
tively, and were undetectable at 60 hours after infection
(Table 1). This indicates that these specific recombinant
OmpA fragments protected the mice against E. coli infec-
tion and that this protection correlated with bacterial
clearance.
Discussion
In Taiwan, maternal Group B streptococcus (GBS) screening
during pregnancy and intrapartum antibiotic prophylaxis
has been promoted since 1996. Like early-onset neonatal
sepsis, although this strategy decreases the incidence of
GBS meningitis, a concurrent increase in the incidence of E.
coli infection has been observed. A 29-year-long assess-
ment of the evolving trends of neonatal and childhood
bacterial meningitis in northern Taiwan revealed GBS and E.
coli as the two most common pathogens of neonatal men-
ingitis; E. coli, however, was the most common pathogen of
neonatal meningitis in 2008e2012.3
Table 1 Remnant bacteria in the brain after Escherichia coli infection.a
Time after
infection (h)
Mean colony-forming unit (SD)/brain
12 24 36 48 60
RS218 (2.3  0.3)  106 (2.4  0.2)  107 (6.0  0.3)  107 NT NT
RS218 þ L1e2 (8.5  0.2)  105 (4.0  0.2)  106 (1.5  0.3)  107 (3.8  0.1)  107 (8.6  0.1)  107
RS218 þ L1e3 (6.0  0.2)  105 (5.4  0.4)  105 (2.6  0.5)  105 (1.0  0.2)  105 ND
RS218 þ L1e4 (1.1  0.2)  106 (4.5  0.4)  106 (1.8  0.2)  107 (4.3  0.1)  107 (9.2  0.0)  107
RS218 þ L2e3 (5.6  0.1)  105 (3.2  0.1)  105 (1.2  0.2)  105 ND ND
RS218 þ L2e4 (5.6  0.2)  105 (5.5  0.4)  105 (2.5  0.3)  105 (1.0  0.2)  105 ND
RS218 þ L3e4 (1.3  0.3)  106 (5.0  0.3)  106 (1.8  0.2)  107 (4.3  0.2)  107 (8.8  0.1)  107
a Groups of three mice were inoculated intracerebrally with 5  105 E. coli RS218. Brain was collected at various time points after
treatment. Remnant bacteria in brain were quantified.
L Z loop; ND Z not detectable; NT Z not tested.
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coli to adhere to and invade into BMECs and astrocytes, and
this binding is the most critical step for E. coli K1 infec-
tion.21,22 OmpA consists of 325 amino acids, and its N-ter-
minal b-barrel domain is essential for effective folding and
function. OmpA proteins lacking C-terminal residues
228e325 or 194e325 are effectively incorporated into the
outer membrane and confer all known OmpA pheno-
types.23,24 Moreover, purified N-terminal amino acids 1e171
of OmpA bind directly to BMECs, whereas a derivative
lacking all four extracellular loops cannot.10 Reportedly,
preincubation of BMECs with OmpA, solubilized from the
outer membrane of OmpAþ E. coli, inhibited E. coli inva-
sion.20 Similarly, the purified N-terminal OmpA also
decreased the association of E. coli K1 with BMECs dose-
dependently.10 We previously reported that the recombi-
nant, full-length OmpA protein can protect astrocytes by
avoiding their activation after E. coli infection.21 In addi-
tion, bacterial entry into BMECs is governed by L1, L2, and
L3.25 Notably, the short peptides corresponding to L1 and
L2 can block the OmpAþ E. coli invasion of BMECs.20 In
addition, the OmpA regions in L1, L2, and L4 resist serum
bactericidal activity through increased binding to a com-
plement regulator protein, C4b-binding protein. Moreover,
the OmpA regions in L1 and L2 are responsible for survival in
tissues and/or blood, resulting in high-grade bacteremia,
which is a prerequisite for the onset of meningitis.26
Based on our research, this is the first report demon-
strating that recombinant OmpA fragments can protect
mice from infection caused by the intracerebral injection
of E. coli RS218. The remnant bacteria in brains infected
with E. coli RS218 along with recombinant OmpA fragments
L1e3, L2e3, and L2e4 were almost undetectable at 60
hours after infection. These data therefore indicate that
the OmpA fragments L1e3, L2e3, and L2e4 can protect
mice from severe neuronal damage and death. In bacterial
meningitis, although antibiotic therapy is the first choice
for management, neurological complications can seldom be
averted. Thus, the possible protective effects and routes of
administration of recombinant OmpA fragments for pa-
tients with bacteremia require further investigation.
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